IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
PsychosisAutoimmune Encephalitis
Interventions
DRUG

Intravenous immunoglobulin

This is a blood product containing antibodies from thousands of healthy donors.

DRUG

Placebo

This is the control, or sham, treatment

DRUG

Rituximab

Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation

Trial Locations (10)

Unknown

RECRUITING

Cambridge University Hospitals NH Foundation Trust, Cambridge

RECRUITING

Royal Devon and Exeter NHS Foundation Trust, Exeter

RECRUITING

NHS Greater Glasgow and Clyde, Glasgow

RECRUITING

The Walton Centre NHS Foundation Trust, Liverpool

RECRUITING

King's College Hospital NHS Foundation Trust, London

RECRUITING

Salford Royal NHS Foundation Trust, Manchester

RECRUITING

Nottingham University Hospitals NHS Trust, Nottingham

RECRUITING

Oxford University Hospitals NHS Foundation Trust, Oxford

RECRUITING

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

NW1 2PG

RECRUITING

University College London Hospitals Nhs Foundation Trust, London

All Listed Sponsors
collaborator

University of Oxford

OTHER

lead

University of Cambridge

OTHER